TP53 and carcinoma: TP53-mutated carcinomas with TP53 NT were associated with a shorter median EFS (18 months) compared to the TP53 WT tumors (116 months, p = 0.014), whereas the TP53 OT showed no statistical tendency toward poorer EFS (96 months, p = 0.962, Fig. 1).